U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer December 4, 2023
Subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types December 4, 2023
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer December 4, 2023
Completion of the Safety Lead-In and Opening of Ph 2 of the AIPAC-003 Ph 2/3 Trial in Metastatic Breast Cancer Announced November 7, 2023
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC October 31, 2023
BriaCell Partners with NYCBS for Pivotal Ph3 Study of Bria-IMT in Advanced Breast Cancer October 11, 2023
Fast Track Designation for IDE161 for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 mutant Breast Cancer October 3, 2023
MHLW approves Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer October 3, 2023
Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial September 26, 2023
European Commission Approves ORSERDU in Patients with ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer September 26, 2023
Tecentriq subcutaneous (SC) is approved in Great Britain for all indications of IV Tecentriq, offering a faster, more convenient option to receive treatment September 6, 2023
Ph 3 Trial of TUKYSA + ado-trastuzumab emtansine Meets Primary Endpoint of PFS in Patients with Previously Treated HER2+ve Metastatic Breast Cancer August 23, 2023
Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial August 16, 2023
Ph 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer August 2, 2023
European Commission Approves Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer August 2, 2023
Positive CHMP Opinion to ORSERDU® (Elacestrant) for ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer patients July 22, 2023
Eisai Transfers All Future Economic Rights for Elacestrant, a Selective Estrogen Receptor Degrader, to DRI Healthcare July 19, 2023
Enhertu approved in China as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer July 19, 2023
Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer June 21, 2023
